MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats

European Journal of Pharmacology

Volumn 336, Issue 1, 1997, Pages 7-14

  Elger, Bernd ^a   Hornberger, Wilfried ^a   Schwarz, Margarete ^a  

^a Knoll AG   (Germany)

Author keywords

Ancrod; Cerebral ischemia; Delayed therapy; Fibrinogen; Hypertensive rat; Middle cerebral artery occlusion; MRI (magnetic resonance imaging); Therapeutic window

Indexed keywords

ANCROD; FIBRINOGEN;

ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANCROD; ANIMALS; BRAIN; BRAIN ISCHEMIA; CEREBRAL ARTERIES; FIBRINOGEN; FIBRINOLYTIC AGENTS; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, INBRED SHR; TIME FACTORS;

EID: 0030781154     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01217-X     Document Type: Article

References (40)

1. Allegrini P.R., Sauer D. Application of magnetic resonance imaging to the measurement of neurodegeneration in rat brain: MRI data correlate strongly with histology and enzymatic analysis. Magn. Reson. Imaging. 10:1992;773-778.
2. Aronowski J., Strong R., Grotta J.C. Treatment of experimental focal ischemia in rats with lubeluzole. Neuropharmacology. 35:1996;689-693.
3. Aronowski J., Strong R., Grotta J.C. Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia. Stroke. 27:1996;1571-1577.
4. Azzimondi G., Bassein L., Fiorani L., Nonino F., Montaguti U., Celin D., Re G., D'Alessandro R. Variables associated with hospital arrival time after stroke. Effect of delay on the clinical efficiency of early treatment. Stroke. 28:1997;537-542.
5. Chen J., Graham S., Moroni F., Simon R. A study of the dose dependency of a glycine receptor antagonist in focal ischemia. J. Pharmacol. Exp. Ther. 267:1993;937-941.
6. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
7. Coull B.M., Beamer N., de Garmo P., Sexton G., Nordt F., Knox R., Seaman G.V.F. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk factors for stroke. Stroke. 22:1991;162-168.
8. De Graba T.J., Ostrow P., Hanson S., Grotta J.C. Motor performance, histologic damage, and calcium influx in rats treated with NBQX after focal ischemia. J. Cereb. Blood Flow Metab. 14:1994;262-268.
9. Eisenberg S. Blood viscosity and fibrinogen concentration following cerebral infarction. Circulation. 33 (Suppl. 2):1966;II10-II14.
10. Elger B., Seega J., Raschack M. Oedema reduction by levemopamil in focal cerebral ischaemia of spontaneously hypertensive rats studied by magnetic resonance imaging. Eur. J. Pharmacol. 254:1994;65-71.
11. Elger B., Laux V., Hornberger W., Schwarz M., Seega J. MRI in vivo of intracerebral haemorrhage and intravital microscopy of haemostatic plug formation in rats: Advantageous effects of ancrod. J. Cereb. Blood Flow Metab. 15 (Suppl. 1):1995;S395.
12. Elger B., Raschack M., Riechers H., Seega J., Unger L. Selective endothelin A receptor antagonist LU 135252 reduces focal cerebral oedema and infarction in spontaneously hypertensive rats. Cerebrovasc. Dis. 6(suppl 2):1996;41.
13. Elger, B., Laux, V., Schwarz, M., 1997. Magnetic resonance imaging studies on the effect of the fibrinogen-lowering agent ancrod on cerebral lesions in two rat models of acute stroke. Arzneim.-Forsch./Drug Res., in press.
14. Eschenfelder, V., 1996. Ancrod as an antithrombotic and thrombolytic agent. In: Zavoico, G., Sussman, C., Savage, L. (Eds.), Advances in Anticoagulant, Antithrombotic and Thrombolytic Therapeutics. IBC Biomedical Library Series, Southborough, pp. 6.3.1.-6.3.12.
15. Ewart M.R., Hatton N.W.C., Basford J.M., Dodgson K.S. The proteolytic action of arvin on human fibrinogen. Biochem. J. 118:1970;603-609.
16. Ginsberg M.D., Busto R. Rodent models of cerebral ischaemia. Stroke. 20:1989;1627-1642.
17. Graham S.H., Chen J., Lan J.Q., Simon R.P. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischaemia. J. Pharmacol. Exp. Ther. 276:1996;1-4.
18. Harper G.D., Haigh R.A., Potter J.F., Castleden C.M. Factors delaying hospital admission after stroke in Leicestershire. Stroke. 23:1992;835-838.
19. Herderscheê D., Limburg M., Hijdra A., Bollen A., Pluvier J., TeWater W. Timing of hospital admission in a prospective series of stroke patients. Cerebrovasc. Dis. 1:1991;165-167.
20. Holleman W.H., Chen L.J. Characterization of peptides released from human fibrinogen by arvin. Biochim. Biophys. Acta. 200:1970;587-589.
21. Hsu C.Y. Criteria for valid preclinical trials using animal stroke models. Stroke. 24:1993;633-636.
22. 2 reactivity during hypocapnia in normal subjects. Stroke. 27:1996;1328-1332.
23. Jorgensen H.S., Nakayama H., Reith J., Raaschou H.O., Olsen T.S. Factors delaying hospital admission in acute stroke: The Copenhagen Stroke Study. Neurology. 47:1996;383-387.
24. Kant K.S., Dosekun A.K., Chandran K.G.P., Glas-Greenwalt P., Weiss M.A., Pollak V.E. Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: In-vivo and in-vitro observations. Thromb. Res. 27:1982;651-658.
25. Margaill I., Parmentier S., Callebert J., Allix M., Boulu R.G., Plotkine M. Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. J. Cereb. Blood Flow Metab. 16:1996;107-113.
26. Paxinos, G., Watson, C., 1986. The rat brain in stereotactic coordinates. Sydney, Australia, Academic Press.
27. Pollak V.E., Glas-Greenwalt P., Olinger C.P., Wadhwa N.K., Myre S.A. Ancrod causes rapid thrombolysis in patients with acute stroke. Am. J. Med. Sci. 299:1990;319-325.
28. Prentice C.R.M., Hampton K.K., Grant P.J., Nelson S.R., Nieuwenhuizen W., Gaffney P.J. The fibrinolytic response to ancrod therapy: Characterization of fibrinogen and fibrin degradation products. Br. J. Haematol. 83:1993;276-281.
29. Roussel S., Pinard E., Seylaz J. Effect of MK-801 on focal brain infarction in normotensive and hypertensive rats. Hypertension. 19:1992;40-46.
30. Satoh, K., Tsuda, Y., Takahashi, T., Kitadai, M., Ichihara, S.-I., Ayada, Y., Hosomi, N., Miyamoto, Y., Matsuo, H., 1993. Hemorheological alterations after onset of cerebral infarction. In: Tomita, M., Mchedlishvili, G., Rosenblum, W., Heiss, W.-D., Fukuuchi, Y. (Eds.), Microcirculatory Statis in the Brain. Elsevier Science Publishers B.V., Amsterdam, pp. 509-516.
31. Sauter A., Rudin M. Strain-dependent drug effects in rat middle cerebral artery occlusion model of stroke. J. Pharmacol. Exp. Ther. 274:1995;1008-1013.
32. Seega J., Elger B. Diffusion- and T2-weighted imaging: Evaluation of oedema reduction in focal cerebral ischaemia by the calcium and serotonin antagonist levemopamil. Magn. Reson. Imaging. 11:1993;401-409.
33. 1 ganglioside treatment of focal ischemia: A dose-response and microdialysis study. J. Pharmacol. Exp. Ther. 265:1993;24-29.
34. Swan J.H., Leach M.J. Evaluation of the novel neuroprotective agent BW 619C89 in the middle cerebral artery occlusion model of focal ischaemia in the spontaneously hypertensive rat and normotensive Fischer 344 rat. Ann. N.Y. Acad. Sci. 765:1995;39-46.
35. Tamura A., Graham D.I., McCulloch J., Teasdale G.M. Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 1:1981;53-60.
36. Tanahashi N., Tomita M., Kobari M., Takeda H., Yokoyama M., Takao M., Fukuuchi Y. Platelet activation and erythrocyte aggregation rate in patients with cerebral infarction. Clin. Hemorheol. 16:1996;497-505.
37. The Ancrod Stroke Study Investigators Ancrod for the treatment of acute ischemic brain infarction. Stroke. 25:1994;1755-1759.
38. Touzani, D., Young, A.R., MacKenzie, E.T., 1994. The window of therapeutic opportunity following focal cerebral ischaemia. In: Krieglstein, J., Oberpichler-Schwenk, H. (Eds.), Pharmacology of Cerebral Ischaemia. Wiss. Verlagsgesellschaft Stuttgart, pp. 575-588.
39. Young A.R., Touzani O., Derlon J.-M., Sette G., MacKenzie E.T., Baron J.-C. Early reperfusion in the anesthetized baboon reduces brain damage following middle cerebral artery occlusion. A quantitative analysis of infarction volume. Stroke. 28:1997;632-638.
40. Zhang F., Iadecola C. Reduction of focal cerebral ischemic damage by delayed treatment with nitric oxide donors. J. Cereb. Blood Flow Metab. 14:1994;574-580.